U.S. markets open in 5 hours 32 minutes
  • S&P Futures

    +18.25 (+0.46%)
  • Dow Futures

    +92.00 (+0.27%)
  • Nasdaq Futures

    +82.00 (+0.71%)
  • Russell 2000 Futures

    +11.80 (+0.64%)
  • Crude Oil

    +1.57 (+2.03%)
  • Gold

    +15.70 (+0.89%)
  • Silver

    +0.38 (+1.78%)

    +0.0044 (+0.43%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +1.53 (+7.46%)

    +0.0090 (+0.75%)

    -0.8770 (-0.63%)

    +268.52 (+1.65%)
  • CMC Crypto 200

    +9.97 (+2.62%)
  • FTSE 100

    +63.44 (+0.85%)
  • Nikkei 225

    -134.99 (-0.48%)

iSpecimen to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. Dr. Ianelli's corporate presentation will be available on-demand starting Monday, January 10th at 7:00 a.m. ET.

For more information about the H.C. Wainwright BioConnect Conference, or to schedule a one-on-one meeting with iSpecimen's management, please contact your H.C. Wainwright representative directly or KCSA Strategic Communications at iSpecimen@kcsa.com.

About iSpecimen
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss

Media Contact
Kaitlynn Cooney
For iSpecimen


View original content to download multimedia:https://www.prnewswire.com/news-releases/ispecimen-to-participate-in-the-hc-wainwright-bioconnect-conference-on-january-10-13-2022-301453120.html

SOURCE iSpecimen Inc.